In non-immune pathways, ERK1/2 activity is associated with defects in mitochondrial morphology and function in AD [108] as well as mitochondrial biogenesis defects and dopaminergic neuronal degeneration in PD [109,110]. The gene discussed is MAPK3; the disease is Alzheimer disease.